Monthly research recap
Depression research: September 2026
What September 2026's 25 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
Research indexed in September 2026 on depression was dominated by treatment-resistant depression (TRD), where ketamine/esketamine and psilocybin showed rapid symptom reductions, though durability was consistently short and evidence quality limited. Head-to-head pooled data found intravenous ketamine and ECT did not differ significantly on response or remission, but heterogeneity was high and removing one large trial produced an ECT advantage. Psilocybin reviews reported rapid, often large effects with some sustained benefit, while biomarker and mechanism studies remained inconsistent and exploratory. The main caveats are small samples, unblinding, strict trial selection, and short follow-up.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| KETAMINE VERSUS ELECTROCONVULSIVE THERAPY FOR SEVERE TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF EFFICACY, SPEED OF RESPONSE, COGNITIVE OUTCOMES, AND SAFETY 2026 | systematic review and meta-analysis | 1388 | Mixed | Pooled response and remission did not differ significantly between intravenous ketamine and ECT, but heterogeneity was high and largely attributable to one trial; omitting it produced a significant ECT advantage, with ECT favoured in hospitalised, severely ill, psychotic populations and ketamine showing non-inferiority plus better short-term neurocognition in ambulatory, non-psychotic populations. |
| Multimodal predictors of response to intravenous ketamine in treatment-resistant depression: toward personalized treatment in major depressive and bipolar disorders. 2026 | systematic review | 150 | Unclear | Identifies candidate predictors of intravenous ketamine response spanning clinical phenotype, inflammatory and neuroplastic biomarkers, metabolic factors, genetics, neurophysiology, and cognition, but argues most predictors remain exploratory and require prospective validation. |
| Symptom-level and network analyses of ketamine treatment in treatment-resistant depression: A pooled analysis of two randomized controlled trials. 2026 | post hoc analysis of pooled randomized controlled trials | 132 | Supports | Ketamine 0.5 mg/kg produced broad early improvement across depression symptoms, with adjusted control-minus-ketamine differences of about 1.1 points on apparent sadness, pessimistic thoughts, and suicidal thoughts at 240 minutes and all four symptom domains differing at 240 minutes and day 2, though exploratory network associations were sensitive to reporting thresholds. |
| Ketamine for Treatment-Resistant Depression in Adolescents: Hope or Risk? 2026 | narrative review | Mixed | Argues ketamine shows short-term efficacy in adolescent treatment-resistant depression, often improving symptoms within 24 hours, but effects are generally short-lived, and use should remain limited to specialized settings until long-term safety and efficacy are confirmed. | |
| Peripheral Biomarkers of Response to Ketamine and Esketamine Treatment in Unipolar Depressive Disorder—A Scoping Review 2026 | systematic review | 46 | Unclear | Across 46 studies the most frequently examined peripheral biomarkers were BDNF, inflammatory markers, and kynurenine pathway metabolites, but results were inconsistent and no biomarker is yet sufficiently consistent for clinical implementation. |
| Feasibility and tolerability of virtual reality during esketamine treatment: A pilot study. 2026 | pilot feasibility and tolerability study | 26 | Mixed | Patients commonly reported auditory and visual discomfort during ketamine treatment and most were open to virtual reality; in five patients who used VR during one esketamine session, glasses wearers had difficulty and reported nausea, and all showed reduced altered-state scores, raising the question of whether VR dampens dissociative intensity. |
| The serotonin 1B receptor as a target for the treatment of depression and anxiety 2026 | review | Unclear | Argues that the serotonin 1B receptor is a tractable therapeutic target for mood disorders, citing preclinical evidence of antidepressant-like effects and a requirement for 5-HT1BR signaling in psilocybin's sustained pro-hedonic and anxiolytic actions, while noting limited clinical data from brain-penetrant selective ligands. | |
| EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW 2026 | review | Supports | Concludes that psilocybin with psychological support produces rapid and clinically significant reductions in depressive symptoms in treatment-resistant depression, with efficacy at least comparable to SSRIs and often faster onset, while adverse events are typically mild and transient and large long-term trials are needed. | |
| Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies. 2026 | systematic review and meta-analysis | 11 | No effect | Meta-analyses of 11 magnetic resonance spectroscopy studies found no statistically significant ketamine-related alterations in GABA, glutamate, or Glx levels, with the authors attributing null findings to methodological heterogeneity rather than a true absence of effect. |
| Mindfulness-based cognitive therapy in an interdisciplinary rehabilitation setting: effects on depression, anxiety, and hopelessness 2026 | observational cohort | 130 | Mixed | Patients with moderate-to-severe depressive symptoms at the start of MBCT showed significant reductions in depression, anxiety, and hopelessness after 8 weeks, while those with minimal symptoms showed a slight increase in depressive symptoms and no significant change in anxiety or hopelessness. |
| Single ayahuasca administration mitigates long-term behavioral and neurochemical effects of early-life stress in rats. 2026 | preclinical animal study | Supports | Maternal deprivation increased anxiety- and depressive-like behaviours and neurochemical alterations, and a single dose of ayahuasca attenuated these behavioural and neurochemical changes when assessed 15 days later. | |
| Effectiveness of Mind-Body Therapies on Anxiety, Burnout, Depression, and Stress in Graduate Health Professions Students: A Systematic Review. 2026 | systematic review | 2220 | No effect | Mind-body therapies showed promise for anxiety and stress, but evidence for depression was inconsistent, with only 1 of 7 studies showing improvement, and none of the 3 burnout studies showed positive results. |
| Esketamine for treatment of depression in Huntington's disease: A case report 2026 | case study | 1 | Mixed | Nasal esketamine was followed by rapid mood improvement, with Beck Depression Inventory score dropping from 29 to 5 after three treatment days, but depression worsened again by three months (BDI 20). |
| Default mode network functional connectivity following treatment with conventional antidepressants and (es)ketamine in major depressive disorder: A systematic review 2026 | systematic review | 793 | Mixed | Conventional antidepressants were associated with heterogeneous changes in default mode network resting-state functional connectivity, some related to clinical improvement, whereas ketamine was mostly associated with reductions in DMN rsFC, particularly DMN-limbic connectivity. |
| A randomized controlled trial comparing Mindfulness and Heartfulness meditation programmes on stress, anxiety, depressive symptoms and wellbeing among distance-learning postgraduates 2026 | randomized controlled trial | 73 | Mixed | The group by time interaction was not statistically significant for primary outcomes, indicating no differential change between Mindfulness-based and Heartfulness-based interventions, though both were associated with significant within-group improvements in stress, anxiety, depressive symptoms, and wellbeing after eight weeks. |
| Treatment-Resistant Depression: A Literature Review of Innovative and Emerging Treatment Strategies 2026 | review | Supports | Argues that emerging therapies for treatment-resistant depression, including ketamine and esketamine, rTMS, ECT, psilocybin-assisted therapy, VNS, and DBS, offer promising alternatives for patients not responding to conventional treatment, though further research is needed to optimize outcomes and integrate them into practice. | |
| Exploratory safety, tolerability, and feasibility of psilocybin-assisted psychotherapy for adults with co-occurring treatment-resistant depression and cluster B personality disorders 2026 | secondary analysis of a clinical trial | 10 | Supports | Mean MADRS scores declined from 30.4 pre-treatment to 22.3 at six months and the mean suicidal ideation item fell from 3.2 to 1.2, with substantial heterogeneity between individuals and no serious adverse events. |
| Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review 2026 | narrative review | Supports | Reports that psilocybin and ayahuasca both show rapid reductions in depressive symptoms in treatment-resistant depression, with psilocybin having more robust evidence for sustained effects, but argues trials are constrained by strict selection, blinding difficulties, small samples, and ethical gaps. | |
| Cognitive effects of ketamine and esketamine treatment for major depressive and bipolar disorder: a systematic review. 2026 | systematic review | 2441 | Mixed | In randomized controlled trials, single-dose ketamine 0.5 mg/kg or esketamine 0.25 mg/kg showed inconsistent cognitive effects, with some domain improvements, null findings, and reports of impaired memory recall and processing speed; open-label maintenance ketamine was associated with within-group cognitive improvements of uncertain cause. |
| [The use of psychedelics in psychiatry]. 2026 | review | Mixed | Argues psilocybin produces consistent, often large improvements in major depressive disorder and that a synthetic psilocybin met its primary endpoint in two phase 3 trials in 2025-2026, but contends certainty of evidence remains low or very low for several indications, so psychedelics should be considered experimental. | |
| EFFECTS OF KETAMINE AND ESKETAMINE ON SUICIDAL IDEATION WITHIN THE FIRST 24 HOURS IN ADULTS WITH DEPRESSIVE DISORDERS: VARIABILITY IN CLINICAL FINDINGS AND INTERPRETATIVE CHALLENGES - A NARRATIVE REVIEW 2026 | narrative review | Mixed | Intravenous ketamine may rapidly reduce suicidal ideation in selected adults, but findings were inconsistent across trials, and intranasal esketamine improved depressive symptoms at 24 hours while clinician-rated suicidality did not differ significantly in either ASPIRE trial. | |
| Chronic sensing during subcallosal cingulate deep brain stimulation captures ketamine-associated changes in major depressive disorder 2026 | case study | 1 | Supports | Ketamine administration and affective states were both associated with changes in subcallosal cingulate 23.44 Hz activity but with distinct spectral and temporal patterns, positioning SCC fast-band activity as a context-dependent signal and motivating adaptive deep brain stimulation strategies. |
| Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review 2026 | systematic review | 46 | Supports | Proposes that psilocin may exert antidepressant effects through 5-HT2A receptor activation, BDNF-TrkB signaling, hippocampal neurogenesis, and default mode network remodeling, and reports that single or limited doses, particularly 25 mg, rapidly and sustainably reduce treatment-resistant depression symptoms with efficacy comparable or superior to escitalopram. |
| Intranasal Esketamine Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder with Comorbid Treatment-Resistant Depression: A Six-Month Case Report 2026 | case study | 1 | Supports | During six months of intranasal esketamine, MADRS scores fell from 38 to 17 and Y-BOCS scores from 33 to 14, but the authors state the observation is hypothesis-generating and cannot distinguish a direct anti-obsessional effect from nonspecific factors. |
| Clinical correlates of non-responders to ketamine in terms of self-assessed life engagement among treatment-resistant depression patients. 2026 | retrospective observational analysis | 65 | Mixed | About half of patients (33 of 65, 50.8%) did not respond on a life engagement measure after short-term ketamine; non-response was associated with later depression onset, prior ECT, absence of diabetes, and occupational inactivity, and the authors state findings are preliminary. |
Points of agreement
- Ketamine, esketamine, and psilocybin produce rapid antidepressant effects in treatment-resistant depression, often within hours to days.
- Antidepressant effects of ketamine and psilocybin are frequently short-lived, and durability beyond weeks to months is uncertain.
- Biomarker and mechanism findings for ketamine response are inconsistent and not yet clinically usable.
- Trial evidence is limited by small samples, strict selection criteria, blinding difficulties, and methodological heterogeneity.
Conflicts
- Pooled ketamine versus ECT data found no significant difference, but removing one large trial produced a significant ECT advantage.
- Some reviews report psilocybin efficacy comparable or superior to standard antidepressants, while others rate certainty of evidence as low or very low.
- Ketamine's cognitive effects are reported as improvements in some domains, null in others, and impairments in memory recall and processing speed in randomized trials.
- Ketamine reduced suicidal ideation in some trials but not others, and esketamine improved depressive symptoms without significant clinician-rated suicidality changes.
Gaps
- Long-term durability and relapse data beyond six months are largely absent.
- Blinding integrity and expectancy effects are unresolved in psychedelic and ketamine trials.
- Populations with comorbidity, high suicide risk, or polypharmacy are systematically excluded.
- Optimal dosing, route, and treatment protocols are not standardized.
- Prospective validation of response predictors and peripheral biomarkers is lacking.
- Adolescent and special-population safety data, including effects on the developing brain, are limited.